Therapie der chronisch-entzündlichen Darmerkrankungen

Schlüsselwörter

chronisch-entzündliche Darmerkrankungen - Morbus Crohn - Colitis ulcerosa - Biologika

Keywords

inflammatory bowel disease - Crohn’s disease - ulcerative colitis - biologicals

• Literatur

• 1 Beaugerie L, Sokol H, Seksik P. Noncolorectal malignancies in inflammatory bowel disease: more than meets the eye. Dig Dis 2009; 27: 375-381
• 2 Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395
• 3 Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250
• 4 Eaden J. The data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18 (Suppl. 02) 15-21
• 5 Henriksen M, Jahnsen J, Lygren I et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol 2007; 42: 602-610
• 6 Henriksen M, Jahnsen J, Lygren I et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006; 12: 543-550
• 7 Lichtenstein GR, Yan S, Bala M et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-869
• 8 Parikh A, Leach T, Wyant T et al. Vedolizumab for the treatment of active ulcerative colitis. Inflamm Bowel Dis 2012; 18: 1470-1479
• 9 Romberg-Camps MJ, Dagnelie PC, Kester AD et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009; 104: 371-383
• 10 Rutgeerts P, Van Assche G, Sandborn WJ et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012; 142: 1102-1111
• 11 Schreiber S, Reinisch W, Colombel JF et al. Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis 2012; Jun 15. [Epub ahead of print]
• 12 Toruner M, Loftus Jr EV, Harmsen WS. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936
• 13 Van Assche G, Vermeire S, Ballet V et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 2012; 61: 229-234
• 14 Waetzig GH, Rose-John S. Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin Ther Targets 2012; 16: 225-236